340 related articles for article (PubMed ID: 11010691)
1. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691
[TBL] [Abstract][Full Text] [Related]
2. Over-the-counter human drugs; labeling requirements. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Mar; 64(51):13254-303. PubMed ID: 10557606
[TBL] [Abstract][Full Text] [Related]
3. Labeling requirements for systemic antibacterial drug products intended for human use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Feb; 68(25):6062-81. PubMed ID: 12577966
[TBL] [Abstract][Full Text] [Related]
4. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 May; 64(98):27666-93. PubMed ID: 10558542
[TBL] [Abstract][Full Text] [Related]
5. Over-the-counter human drugs; labeling requirements; final rule; technical amendment. Food and Drug Administration, HHS. Final rule; technical amendment.
Fed Regist; 2000 Jan; 65(1):7-9. PubMed ID: 11010625
[TBL] [Abstract][Full Text] [Related]
6. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
[TBL] [Abstract][Full Text] [Related]
7. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
[TBL] [Abstract][Full Text] [Related]
8. Prescription drug products; revocation of patient package insert requirements--Food and Drug Administration. Final rule.
Fed Regist; 1982 Sep; 47(173):39147-55. PubMed ID: 10258154
[TBL] [Abstract][Full Text] [Related]
9. Nongenital malformations following exposure to progestational drugs: the last chapter of an erroneous allegation.
Brent RL
Birth Defects Res A Clin Mol Teratol; 2005 Nov; 73(11):906-18. PubMed ID: 16206282
[TBL] [Abstract][Full Text] [Related]
10. Drug labeling; sodium labeling for over-the-counter drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Nov; 69(228):69278-80. PubMed ID: 15570675
[TBL] [Abstract][Full Text] [Related]
11. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
[TBL] [Abstract][Full Text] [Related]
12. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
[TBL] [Abstract][Full Text] [Related]
13. Over-the-counter drug products containing colloidal silver ingredients or silver salts. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule.
Fed Regist; 1999 Aug; 64(158):44653-8. PubMed ID: 10558603
[TBL] [Abstract][Full Text] [Related]
14. Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use; required alcohol warning; final rule; compliance date. Food and Drug Administration, HHS.
Fed Regist; 1999 Mar; 64(51):13066-7. PubMed ID: 10557605
[TBL] [Abstract][Full Text] [Related]
15. Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final rule for over-the-counter antitussive drug products; technical amendment. Final rule, technical amendment.
Food and Drug Administration, HHS
Fed Regist; 2007 Nov; 72(230):67639-40. PubMed ID: 18064767
[TBL] [Abstract][Full Text] [Related]
16. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
[TBL] [Abstract][Full Text] [Related]
17. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients--FDA. Final rule.
Fed Regist; 1998 Dec; 63(231):66631-72. PubMed ID: 10338880
[TBL] [Abstract][Full Text] [Related]
18. Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products; technical amendments. Department of Health and Human Services (HHS), Public Health Service (PHS), Food and Drug Administration (FDA). Final rule; technical amendments.
Fed Regist; 1999 Sep; 64(177):49652-5. PubMed ID: 10915461
[TBL] [Abstract][Full Text] [Related]
19. Pediculicide drug products for over-the-counter human use; amendment of final monograph. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(250):75414-8. PubMed ID: 14986677
[TBL] [Abstract][Full Text] [Related]
20. Toll-free number for reporting adverse events on labeling for human drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Oct; 73(209):63886-97. PubMed ID: 19112682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
